Biomerica Announces Third Quarter Financial Results
April 16, 2019 09:18 ET
|
Biomerica, Inc.
IRVINE, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $4,034,822 for the nine months ending February 28, 2019, compared to $4,433,785 for the...
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS)
April 08, 2019 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...
Biomerica Announces Updates for H. Pylori Clinical Studies
February 05, 2019 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) announced today regulatory and clinical advancements in its development program for its H. pylori diagnostic product. ...
Biomerica Announces Second Quarter Financial Results
January 15, 2019 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) today reported net sales of $1,500,791 for the three months ended November 30, 2018, compared to $1,613,636 for the...
Medline and Biomerica sign agreement for distribution of Biomerica’s colorectal screening test to help identify an early warning sign of colorectal cancer
November 28, 2018 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced that is has signed a three year agreement with Medline Industries for the distribution of Biomerica’s EZ...
Biomerica’s Diagnostic Product Guides Exclusionary Diet Treatment to Successfully Alleviate Symptoms of Ulcerative Colitis (UC) in Prospective Clinical Stud
November 07, 2018 09:42 ET
|
Biomerica, Inc.
Eliminating positive foods identified by Biomerica’s diagnostic product showed statistically significant improvements (p<0.05) in both Quality of Life (FDA Instrument) and disease activity (Mayo...
Biomerica Reports 1st Quarter Fiscal 2019 Financials
October 16, 2018 08:30 ET
|
Biomerica, Inc.
Irvine, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,272,870 for the three months ending August 31, 2018, compared to $1,444,483 for the...
Biomerica Announces Fiscal Year End 2018 Financial Results
August 30, 2018 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2018 were $5,564,185...
Biomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea
August 02, 2018 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent...
Biomerica Announces First Patient Enrollment in Clinical Study for New Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy
June 25, 2018 08:19 ET
|
Biomerica, Inc.
Diagnostic Guided Therapy (DGT) is designed to identify patient specific foods, that when removed, may alleviate an individual's IBS symptomsApproximately 45 million Americans suffer from IBS1 Studies...